AEROPERL® 300 Pharma efficiently converts lipid or oil-based APIs—such as simethicone, dimethicone, cannabis extracts, and other hydrophobic actives—into stable, free-flowing powders. Its mesoporous structure absorbs substantial oil loads while maintaining excellent powder flow, enabling easier handling, improved dosing accuracy, and smoother downstream processing. This approach simplifies production of self-emulsifying systems, facilitates capsule filling, and supports the development of lipid-based drug delivery formats that benefit from enhanced bioavailability.
AEROPERL® 300 Pharma by Evonik
Highly absorptive colloidal silicon dioxide designed to improve solubility and processability of pharmaceutical actives. Transform lipid or poorly soluble APIs into stable, free-flowing powders with enhanced dissolution performance.
Product description & functions
AEROPERL® 300 Pharma is a highly absorptive, granular colloidal silicon dioxide developed to tackle one of formulation’s greatest challenges — poor aqueous solubility. With its spherical granules (20–60 µm) and mesoporous structure, it offers exceptional surface area and pore volume, making it the perfect inorganic carrier for solid dispersions, lipid formulations, and micronised APIs.
The material combines all the purity and quality features of the AEROSIL® Pharma family — synthetic, amorphous silica of pharmaceutical grade, compliant with Ph. Eur. and USP/NF monographs, and manufactured under GMP guidelines.
Its granulated nature significantly reduces dusting and improves flow, even when loaded with up to 150 % of its own weight in oil, enabling smooth handling and direct tablet compression
AEROPERL® 300 Pharma supports multiple formulation pathways
- Carrier for lipid or liquid APIs – converts oils or solutions into solid, free-flowing powders.
- Solubility enhancer – increases dissolution rates for poorly soluble APIs (e.g. artemether, itraconazole, celecoxib).
- Inorganic solid dispersion base – stabilises APIs in amorphous form, reducing crystallisation risk.
- Micronisation carrier – prevents re-agglomeration of API crystals, maximising effective surface area
The result: higher bioavailability, simpler processing, and cleaner tablet performance.
Applications
Lipid-based formulations
Wet and dry granulation
In granulation processes, AEROPERL® 300 Pharma functions as a desiccant and flow modifier, helping stabilise moisture-sensitive formulations and improving granule uniformity. Its high surface area and strong moisture-binding capacity support controlled water uptake during wet granulation and reduce clumping during drying. In dry granulation, the material enhances flowability and reduces sticking, resulting in more consistent compaction behaviour. These benefits are particularly valuable in oncology-related oral solid dosage forms where process control and stability are critical.
Amorphous dispersions
The highly porous morphology of AEROPERL® 300 Pharma makes it an effective inorganic carrier for amorphous solid dispersions. APIs with poor aqueous solubility—especially BCS class II and IV actives such as antifungals or anti-inflammatory compounds—can be stabilised within the silica’s mesopores to prevent recrystallisation. This increases surface area exposure to the dissolution medium and enables higher supersaturation levels. The result is significantly improved dissolution rates, supporting enhanced oral bioavailability for otherwise challenging molecules.
Direct tabletting
AEROPERL® 300 Pharma enhances the mechanical stability and performance of directly compressed tablets. Its granulated structure improves powder flow, feeding consistency, and die-filling behaviour, while its absorptive capacity allows uniform incorporation of oily or low-melting APIs. Formulators benefit from stronger tablets with reduced friability and reliable disintegration profiles across formats including ODTs, immediate-release (IR), and controlled-release (CR) systems. The material also helps mitigate common tabletting issues such as sticking, capping, and weight variability.
-
Property
- Type
- Behaviour in water
- Specific surface area (BET)
- Tamped density
- Pore volume
- pH (4 % dispersion)
- Particle size (d50)
- Compliance
- Production
-
Unit
- -
- -
- m²/g
- g/l
- ml/g
- -
- µm
- -
- -
-
Typical value
- Granulated colloidal silicon dioxide
- Hydrophilic
- 260 – 320
- approx. 270
- 1.5 – 1.9
- 3.5 – 5.5
- 20 – 60
- Ph. Eur., USP/NF “Colloidal Silicon Dioxide”
- GMP-compliant (IPEC guidelines)
